Coen C. Paulusma, Annemiek Groen, Cindy Kunne, Kam S. Ho‐Mok, Astrid L. Spijkerboer, D. Rudi de Waart, Frans J. Hoek, Heleen Vreeling, Kees A. Hoeben, Jan van Marle, Ludmila Pawlikowska, Laura N. Bull, Alan F. Hofmann, A. S. Knisely, Ronald P. J. Oude Elferink – 23 June 2006 – Progressive familial intrahepatic cholestasis type 1 (PFIC1, Byler disease, OMIM 211600) is a severe inherited liver disease caused by mutations in ATP8B1. ATP8B1 is a member of the type 4 subfamily of P‐type ATPases, which are phospholipid flippases.

23 June 2006

Neal R. Barshes, Ian W. Udell, Timothy C. Lee, Christine A. O'Mahony, Saul J. Karpen, Beth A. Carter, John A. Goss – 23 June 2006 – Although rare in the pediatric population, the natural history of hepatitis C virus (HCV) recurrence in pediatric patients undergoing orthotopic liver transplantation (OLT) for end‐stage liver disease secondary to HCV has not been well described. We performed an analysis of all 67 pediatric patients (<17 years old) who have undergone OLT for HCV in the United States between 1/1988 and 6/2005. The 67 pediatric patients received a total of 83 OLTs for HCV.

George V. Mazariegos, Kyle A. Soltys, Geoffrey J. Bond, Robert H. Squires, Rakesh Sindhi – 23 June 2006

Simona Urbani, Barbara Amadei, Paola Fisicaro, Daniela Tola, Alessandra Orlandini, Luca Sacchelli, Cristina Mori, Gabriele Missale, Carlo Ferrari – 23 June 2006 – A timely, efficient, and coordinated activation of both CD4 and CD8 T cell subsets following HCV infection is believed to be essential for HCV control. However, to what extent a failure of the individual T cell subsets can contribute to the high propensity of HCV to persist is still largely undefined.

Masanori Ikeda, Ken‐ichi Abe, Masashi Yamada, Hiromichi Dansako, Kazuhito Naka, Nobuyuki Kato – 23 June 2006 – We recently developed a genome‐length hepatitis C virus (HCV) RNA replication system (OR6) with luciferase as a reporter. The OR6 assay system has enabled prompt and precise quantification of HCV RNA replication. Pegylated interferon (IFN) and ribavirin combination therapy is the world standard for chronic hepatitis C, but its effectiveness is limited to about 55% of patients. Newer therapeutic approaches are needed.

James R. Burton, Hugo R. Rosen – 23 June 2006

Andrea De Gasperi, Francesco Baudo – 23 June 2006

T. Jake Liang – 23 June 2006

Mikiko Ueda, Fumitaka Oike, Yasuhiro Ogura, Kenji Uryuhara, Yasuhiro Fujimoto, Mureo Kasahara, Kohei Ogawa, Koichi Kozaki, Hironori Haga, Koichi Tanaka – 13 June 2006 – This report concerns the long‐term outcome of living donor liver transplantation (LDLT) for pediatric patients at a single center. Between June 1990 and December 2003, a total of 600 LDLTs, including 568 primary transplantations and 32 retransplantations, were performed for pediatric patients, who were immunosuppressed with FK506 and low‐dose corticosteroids.